Background. Ocular tuberculosis (OTb) is uncommon and many ID physicians (IDPs) have limited experience with OT. Ophthalmologists now include IGRAs in evaluating idiopathic uveitis, and some IDPs report increased referrals for possible OTb. Our goal was to understand how IDPs approach diagnosis, treatment, and reporting of OTb.
Methods. The Emerging Infections Network surveyed members treating adult ID patients in 2019 about referrals for suspected OTb. The survey used hypothetical case scenarios to evaluate factors influencing the management of possible OTb, and queried involvement of public health agencies.
Results. 754 of 1,379 (55%) physicians responded. 141 (19%) reported ≥1 referral for possible OTb in the past 3 years; 35% of these reported increasing referrals over time. Most frequent indications for referral were uveitis and positive IGRA (60%) and idiopathic uveitis without positive IGRA or TST (33%). For a hypothetical case with uveitis, positive IGRA but no other symptoms, respondents were much more likely (79% vs. 29%) to treat as TB disease if TB risk factors were present. Respondents were more likely to require a positive eye culture or NAAT prior to treating a risk factor-negative patient (39% vs. 12%). 54% of respondents believed <10% of eye specimens were culture or NAAT-positive for suspected OTb. 94% would treat suspected OTb with INH, RIF, PZA ± EMB but duration of treatment varied with 27% stopping therapy for lack of clinical response and 59% continuing for at least 6 months regardless of response. 44% were unsure if improvement should be expected on therapy. One-third of respondents either did not report or reported only culture-confirmed OTb cases on treatment to public health agencies.
Conclusion.
IDPs report increased referrals for possible OTb, mainly for idiopathic uveitis and positive IGRAs. There is considerable practice variation in management of possible OTb. The decision to treat as TB disease is heavily influenced by TB epidemiologic risk factors, and there is heterogeneity in treatment duration and in expectation of response to therapy. Prospective studies to assess treatment responses in OTb and improved collaboration with ophthalmologists are necessary to better manage this emerging syndrome. Treated OTb cases should be reported to public health agencies.
Disclosures. All authors: No reported disclosures. Methods. We identified all patients with microbiologically confirmed active TB in a large, integrated health system (Kaiser Permanente Northern California, or KPNC) from 1997 to 2016. We calculated active TB incidence in KPNC and measured this against California's reported cases. Within KPNC, we compared mortality, hospital, emergency department, and ambulatory care use among persons with active TB to age-, sex-, and year-of-diagnosis-matched cohort of persons without active TB.
The Burden of Active Tuberculosis in an Integrated
Results. Active TB incidence was lower in KPNC (3.4/100,000 person-years) than in California (7.2/100,000 person-years). Among 2,522 active TB cases, early and delayed mortality was high with 7.0% dying within 1 year of diagnosis and 6.2% dying 1-5 years post-diagnosis. Of the 1,957 active TB patients who continued to receive care through KPNC for at least one year post-diagnosis, 603 (30.8%) had at least one hospitalization. In KPNC, active TB patients had higher healthcare utilization than the matched cohort in the one year following diagnosis: 0.6 vs. 0.1 hospitalizations, 9.5 vs. 4.6 days mean length-of-stay, 0.8 vs. 0.3 emergency department visits, and 14.6 vs. 5.9 ambulatory visits.
Conclusion. Patients with active TB disease have substantial mortality and high inpatient and outpatient healthcare utilization. By improving LTBI screening and treatment, large healthcare systems may be able to reduce the burden and costs associated with active TB.
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